Shire and ADHD
Our commitment
- We aim to enable people with life-altering conditions to lead better lives.
- We’re committed to developing new and future generations of ADHD treatment.
- Shire’s acquisition of UCB’s methylphenidate range is the first step in our
ongoing commitment to advocate for better outcomes for those impacted by ADHD in
the UK.
Our support
- We have various initiatives underway to raise understanding
and awareness of ADHD amongst families, caregivers, educators and patients.
- We intend to continue working to raise the understanding
and awareness of ADHD and create a single, comprehensive source of information
and resources for families.
- We actively participate in major medical associations,
conferences, presentations and education programmes and support independent
organisations and key patient groups.
Our future
- We are continuing to develop treatments for children,
adolescents and adults which allow the specialist physician to meet the unique
needs of individuals with ADHD.
|
|
|